Clinical Trial Update: Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Dehydroepiandrosterone (DHEA) for vaginal atrophy has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy

Drugs mentioned

• Dehydroepiandrosterone (DHEA) (dehydroepiandrosterone)

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Vaginal Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2017-06-12